Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Descriptive
Fundamental
Technical
ETF
All
Exchange Index Sector Industry Country
Market Cap. Dividend Yield Float Short Analyst Recom. Option/Short
Earnings Date Average Volume Relative Volume Current Volume Trades
Price Target Price IPO Date Shares Outstanding Float
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 200 Total
STI - Solidion Technology Inc - Stock Price Chart
TickerSTI [NASD]
CompanySolidion Technology Inc
CountryUSA
IndustryElectrical Equipment & Parts
Market Cap59.79MEPS (ttm)-4.05
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y2.60%
P/B-EPS Q/Q-12377.42%
Dividend-Sales Q/Q-
Insider Own78.31%Inst Own2.01%
Insider Trans0.00%Inst Trans0.59%
Short Float4.96%EarningsApr 12/b
Analyst Recom-Target Price-
Avg Volume1.92M52W Range0.37 - 13.85
Solidion Technology, Inc. engages in researching, developing and manufacturing battery components and materials, batteries and related energy storage products for the automotive electric vehicle and other markets. The company was founded on December 14, 2023 and is headquartered in Dallas, TX.
ZNTL - Zentalis Pharmaceuticals Inc - Stock Price Chart
TickerZNTL [NASD, RUT]
CompanyZentalis Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap293.98MEPS (ttm)-3.36
P/E-EPS this Y39.51%
Forward P/E-EPS next Y-34.28%
PEG-EPS past 5Y-50.05%
P/S7.25EPS next 5Y-
P/B0.64EPS Q/Q113.26%
Dividend-Sales Q/Q-
Insider Own12.31%Inst Own113.65%
Insider Trans-0.48%Inst Trans-0.93%
Short Float28.13%EarningsMay 07/b
Analyst Recom2.20Target Price12.11
Avg Volume653.22K52W Range8.25 - 30.53
Jun-18-24Downgrade Wells Fargo Overweight → Equal Weight
Jun-18-24Downgrade Wedbush Neutral → Underperform $15 → $4
Jun-18-24Downgrade Morgan Stanley Overweight → Equal-Weight $38 → $8
Jun-18-24Downgrade Jefferies Buy → Hold $42 → $6
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallagher CamPresident, Interim CFOMay 31 '24Sale11.989,597114,972633,680May 31 06:27 PM
HAUSMAN DIANAChief Medical OfficerMay 09 '24Sale12.623,35642,353373,876May 09 07:46 PM
Epperly Melissa B,Chief Financial OfficerFeb 12 '24Sale11.442,57329,435451,449Feb 12 08:22 PM
Gallagher CamPresidentFeb 12 '24Sale11.441,17313,419643,277Feb 12 08:21 PM
Gallagher CamPresidentFeb 02 '24Sale11.5411,552133,310644,450Feb 05 07:13 PM
AWIN - AERWINS Technologies Inc - Stock Price Chart
TickerAWIN [NASD]
CompanyAERWINS Technologies Inc
CountryUSA
IndustryScientific & Technical Instruments
Market Cap1.60MEPS (ttm)-9.07
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S1.26EPS next 5Y-
P/B-EPS Q/Q407.08%
Dividend-Sales Q/Q-
Insider Own21.91%Inst Own1.09%
Insider Trans0.00%Inst Trans-20.28%
Short Float13.85%Earnings-
Analyst Recom1.00Target Price100.00
Avg Volume1.16M52W Range2.12 - 74.40
AERWINS Technologies, Inc. engages in the development and manufacture of technologies to enable air mobility. It also provides centralized operating system for managing open sky, hoverbikes, drones, shared computing services, blockchain verification, and AI algorithm generation services. The company was founded in 2017 and is headquartered in Los Angeles, CA.
TRNR - Interactive Strength Inc - Stock Price Chart
TickerTRNR [NASD]
CompanyInteractive Strength Inc
CountryUSA
IndustryPersonal Services
Market Cap2.07MEPS (ttm)-126.69
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S1.77EPS next 5Y-
P/B27.53EPS Q/Q50.54%
Dividend-Sales Q/Q131.21%
Insider Own-Inst Own0.45%
Insider Trans-Inst Trans-
Short Float-EarningsApr 02/b
Analyst Recom1.00Target Price60.00
Avg Volume726.05K52W Range2.64 - 158.00
Interactive Strength, Inc. engages in the development and sale of an at-home fitness technology platform. It offers Forme, a digital fitness service that combines fitness hardware products with personal training and coaching services. It operates under the following geographical segments: the United States, the United Kingdom, and Taiwan. The company was founded by Trent A. Ward and Ben Bartlett on May 8, 2017 and is headquartered in Austin, TX.
LPCN - Lipocine Inc - Stock Price Chart
TickerLPCN [NASD]
CompanyLipocine Inc
CountryUSA
IndustryBiotechnology
Market Cap38.41MEPS (ttm)-1.72
P/E-EPS this Y68.15%
Forward P/E-EPS next Y94.00%
PEG-EPS past 5Y19.47%
P/S5.01EPS next 5Y-
P/B1.59EPS Q/Q186.73%
Dividend-Sales Q/Q13751.93%
Insider Own2.91%Inst Own8.94%
Insider Trans0.00%Inst Trans-63.19%
Short Float3.01%EarningsMay 09/b
Analyst Recom1.00Target Price33.00
Avg Volume74.27K52W Range2.31 - 10.85
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.
TSHA - Taysha Gene Therapies Inc - Stock Price Chart
TickerTSHA [NASD]
CompanyTaysha Gene Therapies Inc
CountryUSA
IndustryBiotechnology
Market Cap555.45MEPS (ttm)-1.16
P/E-EPS this Y56.63%
Forward P/E-EPS next Y-14.28%
PEG-EPS past 5Y-137.69%
P/S39.23EPS next 5Y-
P/B10.32EPS Q/Q62.67%
Dividend-Sales Q/Q-27.52%
Insider Own25.20%Inst Own69.91%
Insider Trans0.00%Inst Trans-1.76%
Short Float11.53%EarningsMay 14/a
Analyst Recom1.10Target Price6.95
Avg Volume2.55M52W Range0.50 - 4.32
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manning Paul B10% OwnerNov 17 '23Buy1.63100,000163,00016,566,667Nov 20 07:35 AM
Alam KamranChief Financial OfficerAug 24 '23Sale2.3333,00076,890258,042Aug 25 04:30 PM
Manning Paul B10% OwnerAug 16 '23Buy0.9016,466,66714,820,00016,466,667Aug 16 08:57 PM
Nolan Sean P.Chief Executive OfficerAug 16 '23Buy0.90444,444400,0001,535,545Aug 16 08:52 PM
Stalfort John A IIIDirectorAug 16 '23Buy0.90388,889350,000999,381Aug 16 08:53 PM
QXO - QXO Inc. - Stock Price Chart
TickerQXO [NASD]
CompanyQXO Inc.
CountryUSA
IndustrySoftware - Application
Market Cap60.57MEPS (ttm)-1.85
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S1.09EPS next 5Y-
P/B8.01EPS Q/Q-50.79%
Dividend-Sales Q/Q9.96%
Insider Own0.03%Inst Own20.40%
Insider Trans-99.92%Inst Trans361.03%
Short Float6.35%Earnings-
Analyst Recom1.00Target Price5.00
Avg Volume15.43K52W Range19.12 - 290.00
QXO, Inc. is a business application, technology and consulting company. It is engaged in providing transformative business management solutions, technologies and professional consulting services to small and medium-sized businesses in the manufacturing, distribution and service industries. The firm offers solutions for accounting and business management, financial reporting, enterprise resource planning, warehouse management systems, customer relationship management, and business intelligence. The company was founded on October 3, 2002 and is headquartered in East Hanover, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meller MarkPres., SilverSun TechnologiesJun 10 '24Sale242.4121,6245,241,802174Jun 12 05:11 PM
Meller MarkChief Executive OfficerJun 04 '24Sale18.7942,700802,360174,388Jun 04 07:38 PM
Meller MarkChief Executive OfficerJun 03 '24Sale18.3853,856989,997217,088Jun 04 07:38 PM
Meller MarkChief Executive OfficerMay 31 '24Sale18.8721,640408,273270,944Jun 04 07:38 PM
Meller MarkChief Executive OfficerMar 26 '24Sale12.972,56833,311292,584Mar 26 08:18 PM
NGNE - Neurogene Inc - Stock Price Chart
TickerNGNE [NASD]
CompanyNeurogene Inc
CountryUSA
IndustryBiotechnology
Market Cap393.55MEPS (ttm)-2.65
P/E-EPS this Y-241.98%
Forward P/E-EPS next Y1.52%
PEG-EPS past 5Y-16.09%
P/S-EPS next 5Y25.10%
P/B2.28EPS Q/Q-290.56%
Dividend-Sales Q/Q-
Insider Own10.33%Inst Own83.69%
Insider Trans0.00%Inst Trans-32.38%
Short Float8.40%EarningsMay 10/b
Analyst Recom1.17Target Price51.00
Avg Volume113.72K52W Range12.20 - 53.00
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in January 2018 and is headquartered in New York, NY.
ZAPP - Zapp Electric Vehicles Group Ltd - Stock Price Chart
TickerZAPP [NASD]
CompanyZapp Electric Vehicles Group Ltd
CountryUnited Kingdom
IndustryAuto Manufacturers
Market Cap4.26MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-7.52%
Dividend-Sales Q/Q-
Insider Own53.15%Inst Own8.08%
Insider Trans0.00%Inst Trans-
Short Float1.53%Earnings-
Analyst Recom-Target Price-
Avg Volume1.14M52W Range0.70 - 53.80
Zapp Electric Vehicles Group Ltd. designs, manufactures and sells electric vehicles. It offers maintenance and repair of motorcycles and related parts and accessories. The company was founded by Swin Chatsuwan, Jeremy North, Warin Thanathawee and Kiattipong Arttachariya in 2017 and is headquartered in London, the United Kingdom.
SCNI - Scinai Immunotherapeutics Ltd ADR - Stock Price Chart
TickerSCNI [NASD]
CompanyScinai Immunotherapeutics Ltd ADR
CountryIsrael
IndustryBiotechnology
Market Cap1.99MEPS (ttm)-20.17
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y46.35%
P/S-EPS next 5Y-
P/B-EPS Q/Q-185.60%
Dividend-Sales Q/Q-
Insider Own2.25%Inst Own8.83%
Insider Trans0.00%Inst Trans-
Short Float0.97%EarningsMay 15/a
Analyst Recom1.00Target Price700.00
Avg Volume514.85K52W Range2.23 - 18.70
Jun-17-24 07:56AM Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today? (InvestorPlace) +60.46%
07:40AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-13-24 07:00AM Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity (PR Newswire)
Jun-07-24 07:00AM Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement (PR Newswire) -28.41%
Jun-03-24 10:52AM SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q4 2023 (InvestorPlace) -5.33%
May-24-24 04:01PM Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance (PR Newswire) +12.46% -9.42%
May-15-24 04:01PM Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update (PR Newswire)
May-06-24 09:21AM Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal (PR Newswire)
Apr-10-24 07:00AM Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schn of UMG (PR Newswire)
Apr-08-24 07:00AM Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services (PR Newswire)
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
1234561020